The Insider Jason Ryan Sold 1 shares of Foundation Medicine, Inc. (FMI); Ws Management Lllp Has Boosted Its Generac Hldgs (GNRC) Position

April 5, 2018 - By John Hoffman

Foundation Medicine, Inc. (NASDAQ:FMI) Logo

Ws Management Lllp increased Generac Hldgs Inc (GNRC) stake by 6.44% reported in 2017Q4 SEC filing. Ws Management Lllp acquired 61,154 shares as Generac Hldgs Inc (GNRC)’s stock declined 10.50%. The Ws Management Lllp holds 1.01 million shares with $50.07 million value, up from 950,000 last quarter. Generac Hldgs Inc now has $2.88B valuation. The stock increased 1.12% or $0.51 during the last trading session, reaching $46.21. About 407,896 shares traded. Generac Holdings Inc. (NYSE:GNRC) has risen 20.22% since April 5, 2017 and is uptrending. It has outperformed by 8.67% the S&P500.

The stock decreased 2.43% or $1.8 during the last trading session, reaching $72.25. About 185,839 shares traded. Foundation Medicine, Inc. (NASDAQ:FMI) has risen 134.36% since April 5, 2017 and is uptrending. It has outperformed by 122.81% the S&P500.

Investors sentiment increased to 1.39 in 2017 Q4. Its up 0.11, from 1.28 in 2017Q3. It is positive, as 13 investors sold Foundation Medicine, Inc. shares while 28 reduced holdings. 33 funds opened positions while 24 raised stakes. 10.07 million shares or 3.72% more from 9.71 million shares in 2017Q3 were reported. Whittier Tru owns 44,685 shares for 0.11% of their portfolio. Laurion Cap Mngmt Ltd Partnership holds 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI) for 3,288 shares. Voya Management Ltd Liability Co accumulated 6,598 shares. Metropolitan Life Insurance Com owns 5,144 shares or 0% of their US portfolio. New York-based Citigroup has invested 0% in Foundation Medicine, Inc. (NASDAQ:FMI). D E Shaw Co Incorporated holds 0.01% in Foundation Medicine, Inc. (NASDAQ:FMI) or 74,612 shares. Goldman Sachs Group Inc has invested 0% in Foundation Medicine, Inc. (NASDAQ:FMI). Strs Ohio invested in 13,700 shares or 0% of the stock. 88,700 were reported by Bamco. Boston Llc invested in 190,620 shares or 0.28% of the stock. Wells Fargo & Mn holds 0% or 22,327 shares in its portfolio. Ubs Asset Mngmt Americas Inc holds 3,535 shares or 0% of its portfolio. New York-based Gilder Gagnon Howe & Limited Liability Corp has invested 1.38% in Foundation Medicine, Inc. (NASDAQ:FMI). Northern Trust reported 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI). Deutsche Bancorp Ag stated it has 0% of its portfolio in Foundation Medicine, Inc. (NASDAQ:FMI).

Among 11 analysts covering Foundation Medicine (NASDAQ:FMI), 2 have Buy rating, 0 Sell and 9 Hold. Therefore 18% are positive. Foundation Medicine has $9500 highest and $19 lowest target. $46.13’s average target is -36.15% below currents $72.25 stock price. Foundation Medicine had 16 analyst reports since July 30, 2015 according to SRatingsIntel. The firm has “Market Perform” rating given on Thursday, July 30 by JMP Securities. BTIG Research initiated Foundation Medicine, Inc. (NASDAQ:FMI) rating on Monday, September 14. BTIG Research has “Buy” rating and $30 target. Cowen & Co initiated Foundation Medicine, Inc. (NASDAQ:FMI) rating on Thursday, February 15. Cowen & Co has “Buy” rating and $90.0 target. As per Monday, May 15, the company rating was upgraded by BTIG Research. The firm has “Neutral” rating by BTIG Research given on Wednesday, November 4. The stock of Foundation Medicine, Inc. (NASDAQ:FMI) has “Neutral” rating given on Tuesday, March 7 by Janney Capital. As per Wednesday, March 28, the company rating was maintained by Cowen & Co. The firm has “Neutral” rating by UBS given on Wednesday, September 21. The company was downgraded on Wednesday, September 16 by Wells Fargo. The rating was maintained by Wells Fargo on Thursday, March 8 with “Market Perform”.

Jason Ryan, the Chief Financial Officer of Foundation Medicine Inc, made a sale of 1 shares of the company, valued around $72 U.S. Dollars, estimated based on $72.4 for share. He also unloaded 21,139 shares worth about $1,641,859 USD in the last 30 days. Currently, Mr. Jason, possess 56,022 shares, which accounts for 0.15% of the company’s market capitalization.

Foundation Medicine, Inc. provides various molecular information products in the United States. The company has market cap of $2.67 billion. The companyÂ’s molecular information platform includes proprietary methods and algorithms to analyze specimens across various types of cancer, as well as for incorporating that information into clinical care; and offers genomic information about each patientÂ’s individual cancer, enabling physicians to optimize treatments in clinical practice and biopharmaceutical companies to develop targeted oncology therapies. It currently has negative earnings. It provides clinical products, such as FoundationOne for solid tumors; FoundationOne Heme for blood cancers, or hematologic malignancies, including leukemia, lymphoma, and myeloma, as well as sarcomas and pediatric cancers; Foundation Assay for Circulating Tumor; FoundationFocus CDxBRCA, a diagnostic assay to aid in identifying women with ovarian cancer.

Since October 12, 2017, it had 0 insider buys, and 26 selling transactions for $25.11 million activity. $2.41M worth of Foundation Medicine, Inc. (NASDAQ:FMI) was sold by Pellini Michael J on Tuesday, January 16. Shares for $1.01 million were sold by Ryan Jason. $150,336 worth of stock was sold by Miller Vincent A. on Tuesday, January 2. 9,012 Foundation Medicine, Inc. (NASDAQ:FMI) shares with value of $605,787 were sold by Cox Troy. $1.83M worth of stock was sold by Kafka Steven J. on Tuesday, February 13. Shares for $119,296 were sold by Hesslein Robert W. $95,616 worth of stock was sold by Nallicheri Melanie on Tuesday, January 2.

Analysts await Foundation Medicine, Inc. (NASDAQ:FMI) to report earnings on May, 8. They expect $-1.06 EPS, up 19.08% or $0.25 from last year’s $-1.31 per share. After $-1.05 actual EPS reported by Foundation Medicine, Inc. for the previous quarter, Wall Street now forecasts 0.95% negative EPS growth.

Since January 2, 2018, it had 0 buys, and 3 selling transactions for $2.83 million activity. Another trade for 20,000 shares valued at $980,511 was sold by Jagdfeld Aaron.

Ws Management Lllp decreased G (NASDAQ:GIII) stake by 306,900 shares to 933,100 valued at $34.42 million in 2017Q4. It also reduced American Express Co (NYSE:AXP) stake by 19,600 shares and now owns 272,300 shares. Albemarle Corp (NYSE:ALB) was reduced too.

Foundation Medicine, Inc. (NASDAQ:FMI) Institutional Positions Chart